2018/19 年度流感疫苗中期效力：2018 年 10 月至 2019 年 1 月的六项欧洲研究。
Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019.
机构信息
EpiConcept, Paris, France.
These authors contributed equally to the study and manuscript writing.
出版信息
Euro Surveill. 2019 Feb;24(8). doi: 10.2807/1560-7917.ES.2019.24.1900121.
Influenza A(H1N1)pdm09 and A(H3N2) viruses both circulated in Europe in October 2018-January 2019. Interim results from six studies indicate that 2018/19 influenza vaccine effectiveness (VE) estimates among all ages in primary care was 32-43% against influenza A; higher against A(H1N1)pdm09 and lower against A(H3N2). Among hospitalised older adults, VE estimates were 34-38% against influenza A and slightly lower against A(H1N1)pdm09. Influenza vaccination is of continued benefit during the ongoing 2018/19 influenza season.
2018 年 10 月至 2019 年 1 月期间，甲型 H1N1pdm09 流感病毒和甲型 H3N2 流感病毒均在欧洲传播。六项研究的中期结果表明，初级保健中所有年龄段的 2018/19 年流感疫苗有效性（VE）估计值对甲型流感的有效性为 32%-43%；对甲型 H1N1pdm09 的有效性更高，对甲型 H3N2 的有效性更低。在住院的老年患者中，对甲型流感的 VE 估计值为 34%-38%，对甲型 H1N1pdm09 的估计值略低。在当前的 2018/19 流感季节，流感疫苗接种仍有裨益。
Zotero 插件